MiNK Therapeutics (INKT) Income from Continuing Operations (2020 - 2026)
MiNK Therapeutics (INKT) posted Income from Continuing Operations of 2792787.0 for Q1 2026, down 14.03% sequentially from 2449160.0 in Q4 2025, and down 6.24% YoY from 2978739.59 in Q1 2025.
MiNK Therapeutics (INKT) Income from Continuing Operations (2020 - 2026) Analysis & Trends
MiNK Therapeutics has reported Income from Continuing Operations for 7 years, with the latest figure at 2792787.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 6.24% year-over-year to 2792787.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 19973526.0 (down 47.58% YoY) and the FY2025 annual result came in at 44093000.0, down 254.97% from the prior year.
- Income from Continuing Operations fell to 2792787.0 in Q1 2026 per INKT's latest filing, from 2449160.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 2449160.0 in Q4 2025 and troughed at 13132018.0 in Q1 2022.
- A 5-year average of 6802137.94 and a median of 5450560.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations plunged 250.01% in 2022, then surged 61.69% in 2024.
- Over 5 years, Income from Continuing Operations stood at 7897483.0 in 2022, then soared by 30.98% to 5450560.0 in 2023, then surged by 53.97% to 2509135.0 in 2024, then grew by 2.39% to 2449160.0 in 2025, then retreated by 14.03% to 2792787.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 2792787.0, 2449160.0, and 9322466.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | MiNK Therapeutics | 60.53 Mn | 60.53 Mn | - | -3.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.47 Mn |
| Mar 31, 2026 | -2.79 Mn |
| Dec 31, 2025 | -2.45 Mn |
| Sep 30, 2025 | -9.32 Mn |
| Jun 30, 2025 | -5.41 Mn |
| Mar 31, 2025 | -2.63 Mn |
| Dec 31, 2024 | -2.51 Mn |
| Sep 30, 2024 | -3.29 Mn |
| Jun 30, 2024 | -5.11 Mn |
| Mar 31, 2024 | -3.79 Mn |
| Dec 31, 2023 | -5.45 Mn |
| Sep 30, 2023 | -7.53 Mn |
| Jun 30, 2023 | -10.81 Mn |
| Mar 31, 2023 | -9.90 Mn |
| Dec 31, 2022 | -7.90 Mn |
| Sep 30, 2022 | -12.65 Mn |
| Jun 30, 2022 | -10.96 Mn |
| Mar 31, 2022 | -13.13 Mn |
| Dec 31, 2021 | -7.17 Mn |
| Sep 30, 2021 | -21.45 Mn |